Back to News
Market Impact: 0.35
Rhythm Pharmaceuticals, Inc. Reports Third Quarter 2026 Net Product Revenue of $92.1 million
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Rhythm Pharmaceuticals reported $92.1 million in global IMCIVREE net product revenue for the quarter ended September 30, 2026, up 29% from the prior quarter. The article also says the company recorded a net loss, but the provided text cuts off before giving its amount.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
RYTM0.55
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge